Search

Displaying results 1971 - 1980 of 4575 in total
  1. Drug

    Golimumab

    go.drugbank.com/drugs/DB06674
    ApprovedInvestigational

    Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation...

  2. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.

  3. Drug

    Suramin

    go.drugbank.com/drugs/DB04786
    Investigational

    Suramin is manufactured by Bayer in Germany as Germanin®.

  4. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]

  5. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    It was being developed by Anesiva, but trials have halted. … ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel.

  6. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    [A263506] It was subsequently approved by the FDA in March 2024.[L50386] … Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction.

  7. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.

  8. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    [L12789] It was later approved by Health Canada on 30 April 2010. … [L44483] Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.[L48385].

  9. Drug

    Risedronic acid

    go.drugbank.com/drugs/DB00884
    ApprovedInvestigational

    It functions by preventing resorption of bone[FDA Label][A959].

  10. Drug

    Prednicarbate

    go.drugbank.com/drugs/DB01130
    Approved

    It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.